NEDD8 activating enzyme inhibitor / Protein neddylation is a post-translational modification which transfers the ubiquitin-like protein NEDD8 to a lysine residue of the target substrate through a three-step enzymatic cascade and has been considered as a viable target for the development of new therapeutics for cancer.1 M22 (CAS 864420-54-2) is an inhibitor of NEDD8 activating enzyme (NAE) which was discovered by virtual screening of a small molecule library (50,000 compounds) against the active site of NAE.2 M22 is selective and reversible and inhibits NEDDylation of ubiquitin-conjugating enzyme 12 (UBC12) in a cell-free assay employing recombinant human NAE. It selectively inhibits NEDDylation over SUMOylation and ubiquitination in A549 cells and inhibits their growth (GI50 = 5.5 µM). It has been shown to inhibit tumor growth in a mouse xenograft model (at 60 mg/kg).2
Biochemicals & reagents
864420-54-2
NAE-IN-M22; N-[2-(2,4-dichlorophenyl)ethyl]-1-(phenylmethyl)-4-piperidinamine
1 Zhong et al. (2012), Discovery of a natural product inhibitor targeting protein neddylation by structure-based virtual screening; Biochimie, 94 2457 2 Lu et al. (2016), Discovery of a novel NEDD8 activating enzyme inhibitor with piperidin-4-amine scaffold by structure-based virtual screening; ACS Chem. Biol., 11 1901
-20°C
TARGET: Neddylation -- PATHWAY: Degradation -- RESEARCH AREA: Ubiquitin/Proteasome -- DISEASE AREA: Cancer